Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy

BACKGROUND: Glucocorticoids (GCs) are often used to treat cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The effects of GCs on the efficacy of CAR-T cell treatment in relapsed/refractory multiple myeloma (RRMM) have not been fully established. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xue, Qi, Yuekun, Li, Hujun, Liu, Fengan, Cao, Jiang, Chen, Wei, Wang, Ying, Qi, Kunming, Yan, Zhiling, Zhu, Feng, Li, Zhenyu, Cheng, Hai, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447480/
https://www.ncbi.nlm.nih.gov/pubmed/36081517
http://dx.doi.org/10.3389/fimmu.2022.943004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447480/
https://www.ncbi.nlm.nih.gov/pubmed/36081517
http://dx.doi.org/10.3389/fimmu.2022.943004

Ejemplares similares